Literature DB >> 23225063

Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice.

Kelly A Diggs-Andrews1, Kazuhiro Tokuda, Yukitoshi Izumi, Charles F Zorumski, David F Wozniak, David H Gutmann.   

Abstract

Children with neurofibromatosis type 1 (NF1) are prone to learning and behavioral abnormalities, including problems with spatial learning and attention. The molecular etiology for these deficits is unclear, as previous studies have implicated defective dopamine, cyclic adenosine monophosphate (cAMP), and Ras homeostasis. Using behavioral, electrophysiological, and primary culture, we now demonstrate that reduced dopamine signaling is responsible for cAMP-dependent defects in neuron function and learning. Collectively, these results establish defective dopaminergic function as a contributing factor underlying impaired spatial learning and memory in children and adults with NF1, and support the use of treatments that restore normal dopamine homeostasis for select individuals.
Copyright © 2012 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23225063      PMCID: PMC3608728          DOI: 10.1002/ana.23793

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  20 in total

1.  Gamma neurons mediate dopaminergic input during aversive olfactory memory formation in Drosophila.

Authors:  Hongtao Qin; Michael Cressy; Wanhe Li; Jonathan S Coravos; Stephanie A Izzi; Joshua Dubnau
Journal:  Curr Biol       Date:  2012-03-15       Impact factor: 10.834

2.  The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1.

Authors:  Weidong Li; Yijun Cui; Steven A Kushner; Robert A M Brown; J David Jentsch; Paul W Frankland; Tyrone D Cannon; Alcino J Silva
Journal:  Curr Biol       Date:  2005-11-08       Impact factor: 10.834

3.  Spatial learning deficit in dopamine D(1) receptor knockout mice.

Authors:  M El-Ghundi; P J Fletcher; J Drago; D R Sibley; B F O'Dowd; S R George
Journal:  Eur J Pharmacol       Date:  1999-10-27       Impact factor: 4.432

4.  Treatment of ADHD in neurofibromatosis type 1.

Authors:  Victor-F Mautner; Lan Kluwe; Sarang D Thakker; Robert A Leark
Journal:  Dev Med Child Neurol       Date:  2002-03       Impact factor: 5.449

5.  Spatial memory impairment induced by lesion of the mesohippocampal dopaminergic system in the rat.

Authors:  A Gasbarri; A Sulli; R Innocenzi; C Pacitti; J D Brioni
Journal:  Neuroscience       Date:  1996-10       Impact factor: 3.590

6.  Neurofibromin regulates G protein-stimulated adenylyl cyclase activity.

Authors:  Jiayuan Tong; Frances Hannan; Yinghua Zhu; Andre Bernards; Yi Zhong
Journal:  Nat Neurosci       Date:  2002-02       Impact factor: 24.884

7.  Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder.

Authors:  Shelley L Hyman; E Arthur Shores; Kathryn N North
Journal:  Dev Med Child Neurol       Date:  2006-12       Impact factor: 5.449

8.  Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras.

Authors:  Frances Hannan; Ivan Ho; James Jiayuan Tong; Yinghua Zhu; Peter Nurnberg; Yi Zhong
Journal:  Hum Mol Genet       Date:  2006-03-02       Impact factor: 6.150

9.  Distinct functional domains of neurofibromatosis type 1 regulate immediate versus long-term memory formation.

Authors:  Ivan Shun Ho; Frances Hannan; Hui-Fu Guo; Inessa Hakker; Yi Zhong
Journal:  J Neurosci       Date:  2007-06-20       Impact factor: 6.167

10.  Restored plasticity in a mouse model of neurofibromatosis type 1 via inhibition of hyperactive ERK and CREB.

Authors:  Clare Guilding; Kara McNair; Trevor W Stone; Brian J Morris
Journal:  Eur J Neurosci       Date:  2007-01       Impact factor: 3.386

View more
  37 in total

Review 1.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

2.  Risky Decision Making in Neurofibromatosis Type 1: An Exploratory Study.

Authors:  Rachel K Jonas; EunJi Roh; Caroline A Montojo; Laura A Pacheco; Tena Rosser; Alcino J Silva; Carrie E Bearden
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-03

3.  Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning.

Authors:  Corina Anastasaki; Albert S Woo; Ludwine M Messiaen; David H Gutmann
Journal:  Hum Mol Genet       Date:  2015-03-18       Impact factor: 6.150

4.  Characterization of early communicative behavior in mouse models of neurofibromatosis type 1.

Authors:  Susan E Maloney; Krystal C Chandler; Corina Anastasaki; Michael A Rieger; David H Gutmann; Joseph D Dougherty
Journal:  Autism Res       Date:  2017-08-26       Impact factor: 5.216

5.  Neurofibromatosis type 1 alternative splicing is a key regulator of Ras signaling in neurons.

Authors:  Melissa N Hinman; Alok Sharma; Guangbin Luo; Hua Lou
Journal:  Mol Cell Biol       Date:  2014-04-07       Impact factor: 4.272

Review 6.  Emerging therapeutic targets for neurofibromatosis type 1.

Authors:  James A Walker; Meena Upadhyaya
Journal:  Expert Opin Ther Targets       Date:  2018-05-07       Impact factor: 6.902

7.  Neurofibromatosis type 1 (Nf1)-mutant mice exhibit increased sleep fragmentation.

Authors:  Corina Anastasaki; Nicholas Rensing; Kevin J Johnson; Michael Wong; David H Gutmann
Journal:  J Sleep Res       Date:  2019-01-04       Impact factor: 3.981

Review 8.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

Review 9.  Modeling cognitive dysfunction in neurofibromatosis-1.

Authors:  Kelly A Diggs-Andrews; David H Gutmann
Journal:  Trends Neurosci       Date:  2013-01-08       Impact factor: 13.837

10.  Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1.

Authors:  Kelly A Diggs-Andrews; Jacquelyn A Brown; Scott M Gianino; Joshua B Rubin; David F Wozniak; David H Gutmann
Journal:  Ann Neurol       Date:  2014-02-06       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.